Two oral antibiotics for gonorrhoea clear the FDA in two days

The FDA approved two new oral antibiotics for uncomplicated gonorrhoea within two days of each other this month: gepotidacin, marketed as Bluejepa, on 11 December, and zoliflodacin, marketed as Nuzolvence, on 12 December [s2].

For a disease that has spent two decades running out of treatment options, two approvals in a week is not a coincidence of scheduling. It is the delayed output of two development programmes that started because the last remaining first-line therapy began to fail.

The resistance problem these drugs are answering

Neisseria gonorrhoeae has developed resistance to nearly every antibiotic used against it except ceftriaxone — and resistance to ceftriaxone is now rising [s1]. There are an estimated 82 million new gonorrhoea infections worldwide each year [s1][s2].

The standard regimen these new drugs were tested against is an injection of ceftriaxone plus oral azithromycin [s2][s3]. That regimen works, but it has structural weaknesses independent of resistance: it requires an injection, which requires a clinic, a trained injector, and a cold chain for the product. In much of the world where gonorrhoea burden is highest, each of those is a point where treatment does not happen.

What the zoliflodacin trial showed

Zoliflodacin was tested in a phase 3 trial sponsored and led by GARDP, the Global Antibiotic Research and Development Partnership, enrolling 930 participants across 16 sites in five countries — Belgium, the Netherlands, South Africa, Thailand and the United States [s1]. GARDP describes it as the largest clinical trial ever conducted for a new gonorrhoea treatment, and it included women, adolescents and people living with HIV [s1][s3].

The design compared a single 3-gram oral dose of zoliflodacin against 500 mg of intramuscular ceftriaxone plus 1 gram of oral azithromycin [s3]. It was a non-inferiority trial, which is the appropriate design when the comparator works and the question is whether a more practical option works nearly as well.

On the primary endpoint of microbiological cure at the urogenital site, the difference between groups was 5.31% (95% CI 1.38 to 8.65) in favour of the comparator, meeting both the prespecified 12% non-inferiority threshold and the FDA-specified 10% margin [s3].

Read that carefully, because non-inferiority results invite over-reading in both directions. Zoliflodacin did not beat the standard regimen — the point estimate favours ceftriaxone plus azithromycin, and the confidence interval excludes zero. What the trial established is that the gap is small enough to fall inside a margin agreed in advance. The trial results were published in The Lancet on 11 December [s1].

Both new drugs were found non-inferior to the existing standard therapy [s2].

Why single-dose and oral matters more than the efficacy margin

The FDA approval covers zoliflodacin as a single-dose oral suspension for uncomplicated urogenital gonorrhoea in adults and paediatric patients aged 12 and older weighing at least 35 kg [s1].

CIDRAP's summary of the practical advantages is the part worth keeping: oral administration removes the injection requirement, zoliflodacin requires no mixing or refrigeration, and both drugs offer an option for patients with beta-lactam sensitivities who cannot take ceftriaxone [s2].

A drug that is 5 percentage points behind on cure rate but can be taken in a pharmacy, a community clinic, or an outreach setting without a cold chain may treat more people than one that is marginally better and requires infrastructure. That is a claim about delivery, not about pharmacology, and it will be settled by implementation data rather than by the trial.

The access architecture is the unusual part

Zoliflodacin's rights are split in a way that is rare for a newly approved antibiotic. Innoviva Specialty Therapeutics holds the US marketing authorisation [s1]. Entasis Therapeutics retains rights for major North American, EU and Asia-Pacific markets [s1]. GARDP holds the rights to register and commercialise the drug in more than three-quarters of the world's countries, including all low-income countries [s1][s2] — the markets where gonorrhoea burden is highest and where commercial return is lowest.

That structure exists because the development was funded as a public health project rather than a commercial one. The phase 3 trial's funders included the governments of Germany, the United Kingdom, Japan, the Netherlands, Switzerland and Luxembourg, the Canton of Geneva, the South African Medical Research Council and the Leo Model Foundation [s3].

Whether it delivers is a separate question from whether it is well designed. Holding registration rights is not the same as completing registration: each country requires a submission, a review, and a national decision. The approval in the United States is the first regulatory domino, not the last.

GARDP's Executive Director is Manica Balasegaram; the phase 3 protocol chair was Edward Hook of the University of Alabama at Birmingham [s1][s3].

What is not established

The FDA approval covers uncomplicated urogenital gonorrhoea [s1]. The trial's primary efficacy endpoint was microbiological cure at the urogenital site [s3]; the approved indication does not extend to infection at other anatomical sites.

Nor does approval settle how these drugs should be positioned. Whether either becomes first-line, or is reserved to preserve its usefulness against resistance, is a treatment-guidelines question that national bodies will have to answer.

This article describes regulatory and trial findings. It is not treatment guidance.

What to watch

Whether CDC and WHO treatment guidance changes to incorporate either drug, and in what position. How quickly GARDP moves registrations in the countries where it holds rights. And, over a longer horizon, whether resistance to zoliflodacin's novel mechanism appears in surveillance — the history of this organism is that it eventually finds a way around everything.